BTCC / BTCC Square / Global Cryptocurrency /
Biotech Stock Opportunity Overshadowed by Market Giants

Biotech Stock Opportunity Overshadowed by Market Giants

Published:
2025-08-04 13:52:02
5
2
BTCCSquare news:

While Eli Lilly (LLY) and Novo Nordisk (NVO) dominate investor attention in the weight-management sector, Viking Therapeutics (VKTX) emerges as a undervalued contender with a $3.7 billion market cap. The company's oral GLP-1/GIP candidate, VK2735, is poised for a Phase 2 data release in September 2025—a potential inflection point.

Previous trials showed promising results: the injectable formulation achieved up to 14.7% weight loss over 13 weeks, with 88% of participants exceeding 10% reduction. The upcoming oral data could disrupt the obesity treatment landscape currently led by Wegovy and Zepbound, particularly if it maintains efficacy with improved convenience.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users